LOS ANGELES (PRWEB) MARCH 25, 2021
MACRO Trials (MACRO), a Site Optimization Organization (SOO), announced advancements to their leadership team today. Daniel Perez (he/him/his) has been appointed Chief Executive Officer (CEO), while outgoing CEO, Jonathan Cabin, MD, will assume the role of MACRO’s Chief Medical Officer (CMO).
Under Perez’s leadership (formerly as Chief Operating Officer), MACRO established the framework to build effective operating, regulatory, policy and culture infrastructure to improve the performance of clinical trials. Perez developed and refined MACRO’s thriving business model by implementing a vision to transform clinical research through the reduction of ballooning costs, lengthy drug approval timelines and the underrepresentation of patient participants that are pervasive in the industry.
In his new role as CEO, Perez will elevate current MACRO accomplishments including conducting high quality, compliant orphan drug clinical trials in the rare diseases space. Mastering the complexities of these trials, such as the small number of eligible patients and need for highly skilled clinical expertise, represents an area of additional success and growth. MACRO has consistently achieved high enrollment and patient retention rates, as well as rapid study start up timelines. Along with an investment in technology-enabled automation for doctors to participate in clinical research, MACRO will continue to be a game changer in the industry.